Related Experiment Video
Updated: Nov 15, 2025

Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
KRAS mutation in pancreatic cancer
1Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
Abstract:
Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene. The KRAS oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. A number of inhibitors have been developed against kinase effectors in various Ras signaling pathways. Their clinical activity, however, has been disappointing thus far. More recently, covalent inhibitors targeting the KRASG12C oncoprotein have been developed. These inhibitors showed promising activity in KRASG12C mutant pancreatic cancer in early clinical trials. This review will present an updated summary of our understanding of mutant KRAS function in pancreatic cancer and discuss therapeutic strategies that target oncogenic KRAS signaling in this disease.
Insights
Pancreatic cancer has low survival rates, but new KRAS inhibitors show promise. Targeting the KRAS oncogene offers a potential therapeutic strategy for this challenging disease.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic cancer is a deadly disease with poor prognosis.
- The KRAS oncogene is frequently mutated and drives tumor growth.
- Current therapies targeting KRAS pathways have limited efficacy.
Purpose of the Study:
- To review the role of mutant KRAS in pancreatic cancer.
- To discuss emerging therapeutic strategies targeting KRAS signaling.
- To summarize recent advancements in KRAS-targeted therapies.
Main Methods:
- Literature review of studies on KRAS mutations in pancreatic cancer.
- Analysis of preclinical and clinical data for KRAS-targeted inhibitors.
- Synthesis of information on KRAS signaling pathways and therapeutic interventions.
Main Results:
- KRAS mutations are a key driver in pancreatic cancer.
- Covalent inhibitors targeting KRAS G12C demonstrate early clinical promise.
- Targeting KRAS signaling remains a critical therapeutic avenue.
Conclusions:
- Despite challenges, targeting KRAS offers a viable strategy for pancreatic cancer treatment.
- Novel KRAS inhibitors, particularly for KRAS G12C mutations, represent a significant advancement.
- Further research and clinical trials are essential to optimize KRAS-targeted therapies.
Related Concept Videos
The Ras Gene
Ras is a...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancers Originate from Somatic Mutations in a Single Cell
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

